Given that patients with confirmed CAD receive antiplatelet medications according to established guidelines, TMPRSS2 expression for healthy controls (n=20) was compared to patients with coronary artery disease (CAD, n=10) and, while numerically greater in CAD, was without a statistically significant difference (Figure 2A, p=0.15). Here, TMPRSS2 is linked to coronary artery disorder.